Experience

Davis Polk advised the forward purchasers and the forward sellers in connection with the execution of forward sale agreements relating to an aggregate of 1,212,120 shares of New Jersey…

Davis Polk advised the initial purchasers in connection with a $150 million Regulation S only offering by China South City Holdings Limited of its 11.5% senior notes due 2022. CSC is a…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame Intermédica and Bain Capital, a shareholder of Notre Dame Intermédica, of…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195.6 million public offering of common stock of Forty Seven, …

Davis Polk advised Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc., including coordinating all international regulatory filings.  The acquisition was…

Davis Polk advised the initial purchasers in connection with the $110.5 million Regulation S only offering by Tahoe Group Global (Co.,) Limited of its 11.0% senior notes due 2020. The notes…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $224.3 million offering of common stock of Constellation…

Davis Polk advised LIV Capital Acquisition Corp. on its $70 million initial public offering of 7,000,000 units. Each unit had an initial offering price of $10 and consists of one Class A…

Davis Polk advised Ranpak Holdings Corp. in connection with the $110 million SEC-registered offering of 16,923,077 shares of its Class A common stock, including 1,538,461 shares pursuant to…